Assembly Biosciences, Inc. (ASMB) stock declined over -1.60% intraday to trade at $2.15 a share on NASDAQ. The stock opened with a gain of 2.87% at $2.12 and touched an intraday high of $2.21, rising 2.38% against the last close of $2.1. The stock went to a low of $2.06 during the session.
Number of Shares
Cash Flow per Share
Free Float in %
Sales or Revenue6.25 Million
5Y Sales Change-
Fiscal Year Ends2021-12-30
Assembly Biosciences, Inc., a clinical-stage biotechnology company, discovers and develops therapeutic candidates for the treatment of hepatitis B virus (HBV) infection in the United States. The company's lead product candidate is Vebicorvir, which as completed Phase 2 clinical trials to treat patients with chronic HBV infection. It is also developing ABI-H3733 that has completed Phase 1a clinical study, and ABI-4334, which is in pre-clinical trials for the treatment of HBV. The company has collaboration agreements with BeiGene, Ltd. and Arbutus Biopharma Corporation; and Antios Therapeutics, Inc. to evaluate a triple combination treatment in patients with chronic hepatitis B virus infection. It also has strategic license agreements with Indiana University Research and Technology Corporation; and Door Pharmaceuticals, LLC. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California.
Assembly Biosciences, Inc. (NASDAQ: ASMB) stock price is $2.15 as of the last check on Friday, July 1. During the trading session, ASMB stock reached the peak price of $2.21 while $2.06 was the lowest point it dropped to.
The NASDAQ listed ASMB is part of Biotechnology industry that operates in the broader Health Care sector. Assembly Biosciences, Inc. , a clinical-stage biotechnology company, discovers and develops therapeutic candidates for the treatment of hepatitis B virus (HBV) infection in the United States.
Ms. Lauren Glaser
Sr. VP of Investor Relations & Corp. Affairs
Dr. John G. McHutchison A.O., FRACP, M.D.
CEO, Pres & Director
Mr. Jason A. Okazaki
Chief Operating Officer
Dr. William E. Delaney IV, Ph.D.
Chief Scientific Officer
ASMB stock traded closed the last session at $2.19, which is $-0.04 or -1.60% lower than its previous close of $2.1. ASMB's current trading price is 63.27% lower than its 52-week high of $3.94 where as its distance from 52-week low of 1.32% is -45.30%.
Number of ASMB employees currently stands at -. ASMB operates from 331 Oyster Point Boulevard, Fourth Floor, South San Francisco, CA 94080, United States.
Official Webiste of $ASMB is: https://www.assemblybio.com
ASMB could be contacted at ASMB operates from 331 Oyster Point Boulevard, Fourth Floor, South San Francisco, CA 94080, United States, or at phone #833 509 4583 and can also be accessed through its website.
ASMB stock volume for the day was 317,995 shares while in the previous session number of ASMB shares traded was 218,000 . The average number of ASMB shares traded daily for last 3 months was 460.63 Thousands.
The percentage change in ASMB stock occurred in the recent session was -1.60% while the dollar amount for the price change in ASMB stock was $-0.04.
In the recent session, the day high for ASMB stock was $2.21 while the low for ASMB stock touched on the day was $2.06.
The market value of ASMB currently stands at 101.31 Million with its latest stock price at $2.15 and 48.12 Million of its shares outstanding.